Evotec will leverage its technology platform and will be responsible for lead generation.

Evotec and Ono Pharmaceutical signed a drug discovery agreement targeting a protease chosen by Ono. Under the terms of the agreement, Ono will pay a technology access fee for Evotec’s fragment-based drug discovery platform, research funding, as well as success-based milestones.


EVOlution™ will be used to identify small molecular weight compounds active against the protease target. Additionally, Evotec will characterize active compounds and optimize their potency and selectivity to generate molecules for progression into clinical trials.


The technology platform integrates protein X-ray crystallography, computational chemistry, structural biology, biochemical, and NMR-based fragment screening in combination with fragment libraries.

Previous articlePharmAthene Retains GTC’s Manufacturing Services for Protexia
Next articleProtein Involved in Brain Cell Death After Stroke or Seizure Identified